Business

Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET.

Haemonetics CorporationFebruary 20, 20261
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference

About this update from Haemonetics Corporation

BOSTON , Feb. 20, 2026 /PRNewswire/ --  Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.summitcast.com/view/VSr8zRPFYu9jT7Rm69ptdC/DrZt2UmuNYtnB5faJBzE4N . A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website. ABOUT HAEMONETICS Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/haemonetics-to-present-at-raymond-james-47th-annual-institutional-investors-conference-302693852.html

View stock analysis, news, and events for Haemonetics Corporation

Haemoneticsfireside chatChris Simon

More from Haemonetics Corporation

All Haemonetics Corporation news →